{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T03:40:03Z","timestamp":1756179603519,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40119-025-00408-6","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:50:15Z","timestamp":1748004615000},"page":"439-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1007","volume":"14","author":[{"given":"Zhuang","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangtao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian\u2019an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yida","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yankun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"408_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024;331:778\u201391. https:\/\/doi.org\/10.1001\/jama.2024.0442.","journal-title":"JAMA"},{"key":"408_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102172","volume":"63","author":"J Wang","year":"2023","unstructured":"Wang J, Chen H, Tang Z, Zhang J, Xu Y, Wan K, et al. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. EClinicalMedicine. 2023;63: 102172. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102172.","journal-title":"EClinicalMedicine"},{"key":"408_CR3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/dddt.S289772","volume":"15","author":"A Burton","year":"2021","unstructured":"Burton A, Casta\u00f1o A, Bruno M, Riley S, Schumacher J, Sultan MB, et al. Drug discovery and development in rare diseases: taking a closer look at the tafamidis story. Drug Des Dev Ther. 2021;15:1225\u201343. https:\/\/doi.org\/10.2147\/dddt.S289772.","journal-title":"Drug Des Dev Ther"},{"key":"408_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"key":"408_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2022.100148","volume":"1","author":"H Mazen","year":"2022","unstructured":"Mazen H, Fine NM, Gundapaneni B, Sultan MB, Witteles RM. Improvements in efficacy measures with tafamidis in the tafamidis in transthyretin cardiomyopathy clinical trial. JACC Adv. 2022;1: 100148. https:\/\/doi.org\/10.1016\/j.jacadv.2022.100148.","journal-title":"JACC Adv"},{"key":"408_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15: e008193. https:\/\/doi.org\/10.1161\/circheartfailure.120.008193.","journal-title":"Circ Heart Fail"},{"key":"408_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101667","volume":"48","author":"A Ghoneem","year":"2023","unstructured":"Ghoneem A, Bhatti AW, Khadke S, Mitchell J, Liu J, Zhang K, et al. Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure. Curr Probl Cardiol. 2023;48: 101667. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101667.","journal-title":"Curr Probl Cardiol"},{"key":"408_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5582\/irdr.2023.01030","volume":"12","author":"W Zhi","year":"2023","unstructured":"Zhi W, Liu M, Yang D, Zhang S, Lu Y, Han J. Analysis of marketed orphan drugs in China. Intractable Rare Dis Res. 2023;12:132\u201340. https:\/\/doi.org\/10.5582\/irdr.2023.01030.","journal-title":"Intractable Rare Dis Res"},{"key":"408_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jacc.2006.02.061","volume":"48","author":"A Passantino","year":"2006","unstructured":"Passantino A, Lagioia R, Mastropasqua F, Scrutinio D. Short-term change in distance walked in 6 min is an indicator of outcome in patients with chronic heart failure in clinical practice. J Am Coll Cardiol. 2006;48:99\u2013105. https:\/\/doi.org\/10.1016\/j.jacc.2006.02.061.","journal-title":"J Am Coll Cardiol"},{"key":"408_CR10","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/01.CIR.0000143059.68996.A7","volume":"110","author":"F Hartmann","year":"2004","unstructured":"Hartmann F, Packer M, Coats AJS, Fowler MB, Krum H, Mohacsi P, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004;110:1780\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000143059.68996.A7.","journal-title":"Circulation"},{"key":"408_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ahj.2009.10.022","volume":"159","author":"T Tsutamoto","year":"2010","unstructured":"Tsutamoto T, Kawahara C, Nishiyama K, Yamaji M, Fujii M, Yamamoto T, et al. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. Am Heart J. 2010;159:63\u20137. https:\/\/doi.org\/10.1016\/j.ahj.2009.10.022.","journal-title":"Am Heart J"},{"key":"408_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamacardio.2021.0372","volume":"6","author":"SJ Greene","year":"2021","unstructured":"Greene SJ, Butler J, Spertus JA, Hellkamp AS, Vaduganathan M, DeVore AD, et al. Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction. JAMA Cardiol. 2021;6:522\u201331. https:\/\/doi.org\/10.1001\/jamacardio.2021.0372.","journal-title":"JAMA Cardiol"},{"key":"408_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12955-018-1036-2","volume":"16","author":"Z Yang","year":"2018","unstructured":"Yang Z, Busschbach J, Liu G, Luo N. EQ-5D-5L norms for the urban Chinese population in China. Health Qual Life Outcomes. 2018;16:210. https:\/\/doi.org\/10.1186\/s12955-018-1036-2.","journal-title":"Health Qual Life Outcomes"},{"key":"408_CR14","volume-title":"SF-12: how to score the SF-12 Physical and Mental Health Summary Scales","author":"J Ware","year":"1995","unstructured":"Ware J, Kosinski M, Keller S. SF-12: how to score the SF-12 Physical and Mental Health Summary Scales. Boston: The Health Institute, New England Medical Center; 1995."},{"key":"408_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11136-004-0704-3","volume":"14","author":"CL Lam","year":"2005","unstructured":"Lam CL, Tse EY, Gandek B. Is the standard SF-12 health survey valid and equivalent for a Chinese population? Qual Life Res. 2005;14:539\u201347. https:\/\/doi.org\/10.1007\/s11136-004-0704-3.","journal-title":"Qual Life Res"},{"key":"408_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23:895\u2013905. https:\/\/doi.org\/10.1002\/ejhf.2198.","journal-title":"Eur J Heart Fail"},{"key":"408_CR17","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589.","journal-title":"Eur Heart J"},{"key":"408_CR18","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1111\/bcp.14773","volume":"87","author":"Y Huh","year":"2021","unstructured":"Huh Y, Riley S, Harnisch L, Nicholas T. Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis. Br J Clin Pharmacol. 2021;87:3574\u201387. https:\/\/doi.org\/10.1111\/bcp.14773.","journal-title":"Br J Clin Pharmacol"},{"key":"408_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/cpdd.789","volume":"9","author":"PA Lockwood","year":"2020","unstructured":"Lockwood PA, Le VH, O\u2019Gorman MT, Patterson TA, Sultan MB, Tankisheva E, et al. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 \u00d7 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9:849\u201354. https:\/\/doi.org\/10.1002\/cpdd.789.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"408_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","volume":"6","author":"BW Sperry","year":"2024","unstructured":"Sperry BW, Sultan MB, Gundapaneni B, Tai SS, Witteles RM. Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT. JACC CardioOncol. 2024;6:300\u20136. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.007.","journal-title":"JACC CardioOncol"},{"key":"408_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","volume":"141","author":"M Hanna","year":"2021","unstructured":"Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, et al. Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021;141:98\u2013105. https:\/\/doi.org\/10.1016\/j.amjcard.2020.10.066.","journal-title":"Am J Cardiol"},{"key":"408_CR22","doi-asserted-by":"publisher","first-page":"786322","DOI":"10.3389\/fnagi.2021.786322","volume":"13","author":"HW Hsueh","year":"2021","unstructured":"Hsueh HW, Chao CC, Chang K, Jeng YM, Katsuno M, Koike H, et al. Unique phenotypes with corresponding pathology in late-onset hereditary transthyretin amyloidosis of A97S vs. V30M. Front Aging Neurosci. 2021;13:786322. https:\/\/doi.org\/10.3389\/fnagi.2021.786322.","journal-title":"Front Aging Neurosci."},{"key":"408_CR23","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/clc.23882","volume":"45","author":"W Lin","year":"2022","unstructured":"Lin W, Chattranukulchai P, Lee AP, Lin YH, Yu WC, Liew HB, et al. Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia. Clin Cardiol. 2022;45:898\u2013907. https:\/\/doi.org\/10.1002\/clc.23882.","journal-title":"Clin Cardiol"},{"key":"408_CR24","doi-asserted-by":"publisher","first-page":"1126836","DOI":"10.3389\/fgene.2023.1126836","volume":"14","author":"Z Yongsheng","year":"2023","unstructured":"Yongsheng Z, Chong S, Bingyou L, Jianian H, Haofeng C, Chongbo Z, et al. Prevalence estimation of ATTRv in China based on genetic databases. Front Genet. 2023;14:1126836. https:\/\/doi.org\/10.3389\/fgene.2023.1126836.","journal-title":"Front Genet"},{"key":"408_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13023-019-1235-x","volume":"14","author":"S He","year":"2019","unstructured":"He S, Tian Z, Guan H, Li J, Fang Q, Zhang S. Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy. Orphanet J Rare Dis. 2019;14:251. https:\/\/doi.org\/10.1186\/s13023-019-1235-x.","journal-title":"Orphanet J Rare Dis"},{"key":"408_CR26","doi-asserted-by":"publisher","unstructured":"Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR epidemiology, genetics, and prognostic factors. Methodist Debakey Cardiovasc J. 2022;18:17\u201326. https:\/\/doi.org\/10.14797\/mdcvj.1066.","DOI":"10.14797\/mdcvj.1066"},{"key":"408_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.6515\/acs.202307_39(4).20230610a","volume":"39","author":"CC Wang","year":"2023","unstructured":"Wang CC, Chang WT, Lin YH, Tzeng BH, Chao TH, Hung CL, et al. 2023 expert consensus of the Taiwan Society of Cardiology on the diagnosis and treatment of cardiac amyloidosis. Acta Cardiol Sin. 2023;39:511\u201343. https:\/\/doi.org\/10.6515\/acs.202307_39(4).20230610a.","journal-title":"Acta Cardiol Sin"},{"key":"408_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7:709\u201316. https:\/\/doi.org\/10.1016\/j.jchf.2019.04.010.","journal-title":"JACC Heart Fail"},{"key":"408_CR29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","volume":"86","author":"Y Ochi","year":"2022","unstructured":"Ochi Y, Kubo T, Baba Y, Sugiura K, Miyagawa K, Noguchi T, et al. Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort. Circ J. 2022;86:1121\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-21-0965.","journal-title":"Circ J"},{"key":"408_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","volume":"30","author":"R Rettl","year":"2023","unstructured":"Rettl R, Duca F, Binder C, Dachs TM, Cherouny B, Camuz Ligios L, et al. Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy. Amyloid. 2023;30:127\u201337. https:\/\/doi.org\/10.1080\/13506129.2022.2131385.","journal-title":"Amyloid"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00408-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00408-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00408-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T03:03:10Z","timestamp":1756177390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00408-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00408-6","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"type":"print","value":"2193-8261"},{"type":"electronic","value":"2193-6544"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zhuang Tian, Daoquan Peng, Wei Ma, Jiangtao Yan, Jian'an Wang, Wei Jin, Yida Tang, Ying Liu, and Shuyang Zhang have nothing to disclose. Caiping Jia, Yingxu Gao, Yankun Gong, Xiaohong Sun, Naihan Chen, and Shuiqing Zhu: employees of Pfizer and hold share\/share options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted according to ethical principles derived from the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, and the International Council for Harmonisation Good Clinical Practice guidelines. The study followed all local laws and regulations. Study materials were reviewed and approved by Ethics Committees or Institutional Review Boards at each participating center (Table S1; Approval number at the primary site [Peking Union Medical College Hospital]: KS2021004). All patients (or their legal representatives) provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}